Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD.
about
Lung microbiology and exacerbations in COPDComparing antibiotics for acute exacerbations of chronic obstructive pulmonary diseaseComparing antibiotics for acute exacerbations of chronic obstructive pulmonary diseasePseudomonas infection in chronic obstructive pulmonary diseaseInvestigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD.Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma.Significance of the microbiome in chronic obstructive pulmonary disease.Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease.Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease.Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer.Targeting pro-resolution pathways to combat chronic inflammation in COPDBaicalein attenuates the quorum sensing-controlled virulence factors of Pseudomonas aeruginosa and relieves the inflammatory response in P. aeruginosa-infected macrophages by downregulating the MAPK and NFκB signal-transduction pathways.Clarithromycin targets neutrophilic airway inflammation in refractory asthma.Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations.Multivariate analysis of the risk for pulmonary complication after gastrointestinal surgery.Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammationAirway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function.Quantitative analysis of pathogens in the lower respiratory tract of patients with chronic obstructive pulmonary diseaseBacteria in sputum of stable severe asthma and increased airway wall thicknessThe lung tissue microbiome in chronic obstructive pulmonary disease.Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers.Convergence of the epidemiology and pathology of COPDRaised CRP levels mark metabolic and functional impairment in advanced COPD.Inflammatory cells in the airways in COPD.Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease.Pathogenesis of bacterial exacerbations of COPD.Postoperative pulmonary complications following major elective abdominal surgery: a cohort study.Blood fibrinogen as a biomarker of chronic obstructive pulmonary diseaseNewer fluoroquinolones in the treatment of acute exacerbations of COPDAirway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease.Impact of statins and ACE inhibitors on mortality after COPD exacerbations.Airways inflammation and treatment during acute exacerbations of COPD.Role of macrolide therapy in chronic obstructive pulmonary disease.Targeted treatment in COPD: a multi-system approach for a multi-system disease.Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease.Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial.Prophylactic antibiotic therapy in chronic obstructive pulmonary disease.The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease.The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.Phenotyping the heterogeneity of chronic obstructive pulmonary disease.
P2860
Q22305860-9D1694FE-E5EB-450E-A1A6-7D30E7C7D15CQ24234366-3AE9ACBD-B627-4EE0-9300-35303EFB067DQ24243833-E2646F26-DA2F-4ABD-BB5D-2AD94EC68726Q26996706-BF733A54-B2C0-4D1C-8F2C-823460705B41Q33596515-8723FAD8-6101-453E-8D02-7980C3B7B236Q33793577-12E349C3-FF5B-423E-AA90-7D77F00F8FE3Q33817613-01CA2053-BCD2-4A2A-994A-25EAE408C2A4Q34065677-E6CA5760-715D-4338-94BF-0592282F9461Q34234995-8BF0BDD2-B54E-441F-8E0B-E902E93DD6A8Q34621087-529F2677-98C4-44F9-AB6A-2476118A1B8BQ34628609-9A5B54F0-8A11-495C-84AD-3B8300B60AF2Q34675340-D82E6F27-E2E6-48AA-BB44-CBCFDE26FAA3Q34703625-8FC15036-80EB-4B31-9717-FA3E1A907961Q34840443-7D9B7CC0-C34B-4F1B-951B-EC075324F882Q35045489-2170D7BA-3BD0-4B26-A144-BA9F73EDB6ECQ35594061-825D49DF-666C-45DC-A838-06A88EB2B749Q35746774-ACE42588-F287-4DB6-BC73-4A4283DD5C0AQ35749457-2FE4E8DC-3987-4344-96E7-EC002F1785E5Q35955401-3F862884-6BA2-4D90-870C-1233F744F7DAQ35987112-C39878BB-A026-4A05-8A47-BD9B5784E43AQ36008670-AB6085E4-7F5A-4113-A8FC-DA901D97E0ABQ36148610-516DAC44-9C0F-4519-BD0A-CA67A072236AQ36148662-2A78893E-117B-4374-BABC-8CC20475C1B6Q36203075-D005CD09-53FA-422F-A99A-799AA8505147Q36464916-2944FD89-8CD6-456B-8BBD-D96634362D45Q36686865-2625BA5E-403D-4CE0-9F26-2BEB15ABDB53Q36929018-8477ABD3-C463-4DA8-B057-7EFE6D3435F2Q37012728-C4E6C239-E788-4495-A055-32BFF36AECBAQ37018822-FD4AE95A-75F7-4736-A5F8-06DA1B10A100Q37144323-BDAD97FE-A3F4-477F-AE32-8B0E2518B119Q37231396-AFE00E11-4960-4660-BC8A-6CCDE60144FBQ37237665-6ABC6FB0-2874-465C-8725-5EF763BD41BCQ37319950-D7BC0C02-D5EB-4E8C-844E-BAE2E3DF2F6EQ37340178-DA50282F-DD4D-466B-A5AB-382A2B32B2A6Q37413293-C01B58A0-CCCB-494A-A58E-8BCFAFC5C7C8Q37582484-9D9D5673-CA85-4BE5-AEAB-0EF5497DC98CQ37763372-D025EE48-DE58-4FA8-AAB9-EBD04C67BA17Q37850201-48615B56-4D8A-473C-8581-00E145A55A5EQ38056764-FF03F681-31F9-42BB-90A3-B13CEF20D6A8Q38063326-3F6F3412-8F57-4DB8-AB59-BAC5B53468D2
P2860
Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Impact of sputum bacteria on a ...... tatus in clinical stable COPD.
@en
Impact of sputum bacteria on a ...... tatus in clinical stable COPD.
@nl
type
label
Impact of sputum bacteria on a ...... tatus in clinical stable COPD.
@en
Impact of sputum bacteria on a ...... tatus in clinical stable COPD.
@nl
prefLabel
Impact of sputum bacteria on a ...... tatus in clinical stable COPD.
@en
Impact of sputum bacteria on a ...... tatus in clinical stable COPD.
@nl
P2093
P1476
Impact of sputum bacteria on a ...... tatus in clinical stable COPD.
@en
P2093
D Banerjee
D Honeybourne
P304
P356
10.1183/09031936.04.00056804
P577
2004-05-01T00:00:00Z